Veru Reports Topline Efficacy And Safety Results From Maintenance Extension Portion Of Phase 2b QUALITY Study, Demonstrating that In 12 Weeks After Stopping Semaglutide, Placebo Monotherapy Group Regained 43% Of Body Weight While Enobosarm Monotherapy Reduced Weight Regain By 46%

Author: Benzinga Newsdesk | June 24, 2025 08:33am

--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly reduced body weight regain by 46% and completely prevented fat regain compared to placebo--

--The enobosarm treated groups showed up to 93% greater fat loss and 100% lean mass preservation compared to the placebo group at the end of the study--

--Enobosarm monotherapy had a positive safety profile with essentially no gastrointestinal side effects during the maintenance treatment period--

-- Based on efficacy and safety from Phase 2b QUALITY and Maintenance Extension study:

--Enobosarm 3mg will advance as the proposed oral dose for the Phase 3 clinical program--

--Veru has been granted a meeting with FDA to discuss the Phase 3 clinical program--

Posted In: VERU